Back to Journals » Substance Abuse and Rehabilitation » Volume 3 » Issue 1

Acamprosate in the treatment of alcoholism: a budget impact analysis for the National Health Service in Italy

Authors Colombo G, Di Matteo S, Bruno GM

Received 17 February 2012

Accepted for publication 17 April 2012

Published 17 July 2012 Volume 2012:3(1) Pages 73—79

DOI https://doi.org/10.2147/SAR.S30980

Review by Single-blind

Peer reviewer comments 3

Giorgio L Colombo,1,2 Sergio Di Matteo,2 Giacomo Bruno2

1Department of Drug Sciences, School of Pharmacy, University of Pavia, Pavia, Italy; 2S.A.V.E. – Studi Analisi Valutazioni Economiche, Milan, Italy

Objective: Alcohol dependence is a common condition associated with high direct and indirect health care costs. The purpose of this analysis was to estimate the economic consequences of acamprosate used as adjuvant therapy in the treatment of alcoholism, defining a budget impact analysis (BIA) from the point of view of the Italian National Health Service (NHS).
Methods: We developed a model of disease evolution related to alcoholism using data from the PRAMA study. The hypothetical population included in the decision model was obtained from data from the Ministry of Health. We compared the following treatment strategies: no treatment, standard care (psychotherapy), sodium oxybate (sodium salt-4-hydroxybutyric acid), and acamprosate. The time horizon of the model was 10 years. The costs were evaluated from the NHS perspective.
Results: We simulated the path for 69,348 patients treated at the outpatient clinics of the Addiction Services (SerT), and 38,911 patients discharged from hospital. Patients in the acamprosate group had lower alcohol-related events, with a reduction of the total cost. The BIA shows that the increase in the use of acamprosate was associated with a progressive decrease of total costs, calculated as the sum of the diagnosis-related groups (DRG), rehabilitation, and drug costs. The increasing use of acamprosate instead of standard care and sodium oxybate would generate cost savings up to over €6 million over 10 years of simulation.
Conclusion: The estimates in the model are based on hypothetical situations; the assumptions of the model as well as their specific impact on treatment effect estimations and clinical implications should be validated in real life. Public health care authorities would benefit from mathematical models designed to estimate the future burden of alcohol dependence together with the impact of treatment and the potential to reduce the incidence and progression of this condition, and the costs of its complications.

Keywords: alcohol dependence, acamprosate, budget impact analysis, economic evaluation

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Patterns of treatment and costs of intermediate and advanced hepatocellular carcinoma management in four Italian centers

Colombo GL, Cammà C, Attili AF, Ganga R, Gaeta GB, Brancaccio G, Franzini JM, Volpe M, Turchetti G

Therapeutics and Clinical Risk Management 2015, 11:1603-1612

Published Date: 19 October 2015

Cost-effectiveness analysis of antiretroviral therapy in a cohort of HIV-infected patients starting first-line highly active antiretroviral therapy during 6 years of observation

Maggiolo F, Colombo GL, Di Matteo S, Bruno GM, Astuti N, Di Filippo E, Masini G, Bernardini C

Patient Related Outcome Measures 2015, 6:53-60

Published Date: 17 February 2015

Economic and outcomes consequences of TachoSil®: a systematic review

Colombo GL, Bettoni D, Di Matteo S, Grumi C, Molon C, Spinelli D, Mauro G, Tarozzo A, Bruno GM

Vascular Health and Risk Management 2014, 10:569-576

Published Date: 10 September 2014

Economic evaluation of initial antiretroviral therapy for HIV-infected patients: an update of Italian guidelines

Colombo GL, Matteo SD, Antinori A, Medaglia M, Murachelli S, Rizzardini G

ClinicoEconomics and Outcomes Research 2013, 5:489-496

Published Date: 3 October 2013

A cost-of-illness study of spina bifida in Italy

Colombo GL, Di Matteo S, Vinci M, Gatti C, Pascali MP, De Gennaro M, Macrellino E, Mosiello G, Redaelli T, Schioppa F, Dieci C

ClinicoEconomics and Outcomes Research 2013, 5:309-316

Published Date: 2 July 2013

Cost and appropriateness of treating asthma with fixed-combination drugs in local health care units in Italy

Ruggeri I, Bragato D, Colombo GL, Valla E, Di Matteo S

ClinicoEconomics and Outcomes Research 2012, 4:375-382

Published Date: 5 December 2012

Cost-effectiveness analysis of HIV treatment in the clinical practice of a public hospital in northern Italy

Rizzardini G, Bonfanti P, Carenzi L, Coen M, Orlando G, Di Matteo S, Colombo GL

Therapeutics and Clinical Risk Management 2012, 8:377-384

Published Date: 17 September 2012

Antidiabetic therapy in real practice: indicators for adherence and treatment cost

Colombo GL, Rossi E, De Rosa M, Benedetto D, Gaddi AV

Patient Preference and Adherence 2012, 6:653-661

Published Date: 14 September 2012

Burden of Crohn’s disease: economics and quality of life aspects in Italy

Benedini V, Caporaso N, Corazza GR, Rossi Z, Fornaciari G, Cottone M, Frosini G, Caruggi M, Ottolini C, Colombo GL

ClinicoEconomics and Outcomes Research 2012, 4:209-218

Published Date: 24 July 2012

Cost-effectiveness analysis of initial HIV treatment under Italian guidelines

Colombo GL, Colangeli V, Di Biagio A, Di Matteo S, Viscoli C, Viale P

ClinicoEconomics and Outcomes Research 2011, 3:197-205

Published Date: 31 October 2011

Cost–utility analysis of prophylaxis versus treatment on demand in severe hemophilia A

Giorgio L Colombo, Sergio Di Matteo, Maria Elisa Mancuso, et al

ClinicoEconomics and Outcomes Research 2011, 3:55-61

Published Date: 14 March 2011

A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy

Giorgio L Colombo, Giovanni B Gaeta, Mauro Viganò, et al

ClinicoEconomics and Outcomes Research 2011, 3:37-46

Published Date: 15 February 2011

A cost–utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy

Giorgio L Colombo, Sergio Di Matteo, Ketty Peris, Maria Concetta Fargnoli, et al.

ClinicoEconomics and Outcomes Research 2009, 1:53-59

Published Date: 15 October 2009

Assessment of acceptability and ease of use of atovaquone/proguanil medication in subjects undergoing malaria prophylaxis

V Nicosia, Giorgio Colombo, M Consentino, S Di Matteo, F Mika, et al

Therapeutics and Clinical Risk Management 2008, 4:1105-1110

Published Date: 10 October 2008

Moderate and severe plaque psoriasis: cost-of-illness study in Italy

GL Colombo, GF Altomare, K Peris, P Martini, G Quarta

Therapeutics and Clinical Risk Management 2008, 4:559-568

Published Date: 11 April 2008

Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy

Giorgio L Colombo, Mauro Caruggi, Chiara Ottolini, Aldo P Maggioni

Vascular Health and Risk Management 2008, 4:223-234

Published Date: 8 February 2008

Readers of this article also read:

Emerging and future therapies for hemophilia

Carr ME, Tortella BJ

Journal of Blood Medicine 2015, 6:245-255

Published Date: 3 September 2015

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Topical diclofenac in the treatment of osteoarthritis of the knee

Niklas Schuelert, Fiona A Russell, Jason J McDougall

Orthopedic Research and Reviews 2011, 3:1-8

Published Date: 6 February 2011